Arie Belldegrun (L) and Amir Nashat

Hooked by the sci­ence, Arie Bellde­grun joins a group of in­flu­en­tials who be­lieve Dew­point may have the key to the next big thing in biotech

Amir Nashat knew he had years of pre­clin­i­cal work to do when he talked to me at the be­gin­ning of 2019 about Dew­point Ther­a­peu­tics and its rare fo­cus on the role bi­mol­e­c­u­lar con­den­sates could play in craft­ing a wide-rang­ing pipeline of ther­a­peu­tics.

And he and his grow­ing transat­lantic team of about 70 still have con­sid­er­able work ahead. On­ly now he can count Arie Bellde­grun, ARCH Ven­ture Part­ners and a wider cir­cle of in­flu­en­tial back­ers to go the next leg of the jour­ney — now fund­ed through to the point that they can start to get the first look at what their drugs can do in hu­mans.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.